Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Imcyse","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$180.0 million","upfrontCash":"Undisclosed","newsHeadline":"Imcyse Enters into Research Collaboration and License Agreement for its Imotope\u2122 Technology with Pfizer in Rheumatoid Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"BELGIUM","productType":"Peptide","productStatus":"Undisclosed","date":"February 2021","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical"},{"orgOrder":0,"company":"Imcyse","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Imcyse Raises Additional EUR 21.3 Million in Series B Financing Round - Pfizer Joins as Newest Shareholder","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"BELGIUM","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Immunology","graph2":"Undisclosed"},{"orgOrder":0,"company":"Imcyse","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imcyse Reports Positive Immune Response from Interim Analysis of Phase 2 IMPACT Type 1 Diabetes Study","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"BELGIUM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II"},{"orgOrder":0,"company":"Imcyse","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imcyse Announces Completion of Enrollment in Phase 2 IMPACT Trial of IMCY-0098 for Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"BELGIUM","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II"},{"orgOrder":0,"company":"Imcyse","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imcyse Announces Completion of Enrollment in Phase 1 Clinical Trial of ImotopeTM IMCY-0141 for the Treatment of Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"BELGIUM","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by Imcyse

    Menu

    Imcyse

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Imcyse

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Belgium
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Imcyse Announces Completion of Enrollment in Phase 1 Clinical Trial of ImotopeTM IMCY-0141 for the Treatment of Multiple Sclerosis

              Details:

              IMCY-0141 is the Imotope™ is designed based on myelin oligodendrocyte glycoprotein with the aim to halt the progression of multiple sclerosis (MS) by stopping the body's immune system from attacking the central nervous system.

              Lead Product(s): IMCY-0141

              Therapeutic Area: Neurology Product Name: IMCY-0141

              Highest Development Status: Phase I/ Phase II Product Type: Peptide

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 13, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Imcyse

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Belgium
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Imcyse Announces Completion of Enrollment in Phase 2 IMPACT Trial of IMCY-0098 for Type 1 Diabetes

              Details:

              IMCY-0098, a synthetic peptide based on insulin, is designed to halt the progression of diabetes by stopping the body’s immune system from attacking beta cells. With early intervention, the pancreas’ ability to produce insulin may be preserved to manage the disease.

              Lead Product(s): IMCY-0098

              Therapeutic Area: Endocrinology Product Name: IMCY-0098

              Highest Development Status: Phase II Product Type: Peptide

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 01, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Imcyse

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Belgium
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Imcyse Reports Positive Immune Response from Interim Analysis of Phase 2 IMPACT Type 1 Diabetes Study

              Details:

              Positive interim biomarker Phase 2 IMPACT Type 1 Diabetes Study data support specific immune signature induced by Imotope (IMCY-0098) and effect on potentially pathogenic T cells.

              Lead Product(s): IMCY-0098

              Therapeutic Area: Endocrinology Product Name: Imotope

              Highest Development Status: Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 13, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Imcyse

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Belgium
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Imcyse Raises Additional EUR 21.3 Million in Series B Financing Round - Pfizer Joins as Newest Shareholder

              Details:

              The funding will allow the company advance its lead Imotope candidate for Type 1 Diabetes into phase 2 as well as four other programs in Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorders, Celiac Disease, and Rheumatoid Arthritis.

              Lead Product(s): Imotope

              Therapeutic Area: Immunology Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Peptide

              Partner/Sponsor/Collaborator: Pfizer Inc

              Deal Size: $25.0 million Upfront Cash: Undisclosed

              Deal Type: Series B Financing February 17, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Imcyse

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Belgium
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Imcyse Enters into Research Collaboration and License Agreement for its Imotope™ Technology with Pfizer in Rheumatoid Arthritis

              Details:

              Imcyse and Pfizer will collaborate to develop Imotope™ candidates to potentially treat Rheumatoid Arthritis. Pfizer will lead clinical development and commercialization activities.

              Lead Product(s): Undisclosed

              Therapeutic Area: Immunology Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Peptide

              Partner/Sponsor/Collaborator: Pfizer Inc

              Deal Size: $180.0 million Upfront Cash: Undisclosed

              Deal Type: Collaboration February 03, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY